Immunic Appoints Jaa Roberson as Chief People Officer 

– Appointment Supports Immunic’s Strategy to Build a Leading Multiple Sclerosis Organization Ahead of Potential Transition to Fully Integrated Commercial Company –

NEW YORK, October 19, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Jaa Roberson as Chief People Officer (CPO), effective today. Ms. Roberson will report directly to Chief Executive Officer Erik Lundgren and will serve as a member of the executive leadership team.

The appointment represents another important step in Immunic’s strategy to assemble a team of highly qualified leaders with key experience in building a leading multiple sclerosis (MS) organization. In this newly created executive role, Ms. Roberson will lead the company’s global talent and organizational strategy, with a particular focus on attracting and developing the specialized capabilities required as Immunic prepares for its pivotal Phase 3 ENSURE read-out expected by the end of 2026, as well as potential regulatory filings and commercialization of vidofludimus calcium (IMU-838).

“Over the past several months, we have been assembling a leadership team with deep experience in MS and a track record of successfully developing and commercializing important therapies for patients,” said Erik Lundgren, Chief Executive Officer of Immunic. “Our continued goal is to build an exceptional MS organization with the right people and capabilities in place. I am thrilled that Jaa joins us at this critical time, with the pivotal Phase 3 data in relapsing MS expected by year-end and our progressive MS trial preparations advancing. Jaa will be a strategic partner on the management team helping us attract, develop, and retain world-class talent while building the structures, systems, and culture necessary for scaling from a research and development biotechnology company toward a fully integrated commercial organization.”

“I am excited to join Immunic at such an important stage in the company’s evolution,” said Jaa Roberson, Chief People Officer of Immunic. “Immunic has assembled a strong leadership team with deep experience across MS research and development, regulatory and commercialization. With the pivotal Phase 3 data approaching, my focus will be on building the broader organization and continuing to attract the specialized talent, capabilities, and culture needed to support potential regulatory approval and commercialization, while preserving the agility and focus that differentiate Immunic as a biotechnology company.”

Ms. Roberson is a people leader with more than two decades of human resources (HR) experience across the biopharma, health insurance, and retail industries, successfully leading companies through growth, transformation and change by building high performance, diverse and inclusive organizations where everyone thrives, contributes and grows to drive impactful patient and business outcomes. Most recently as Chief People Officer at Day One Biopharmaceuticals, she guided the organization to scale and grow from 37 to 200 employees while maintaining strong engagement and retention, successfully transition from clinical to commercial stage following the approval and launch of OJEMDA® (pediatric low-grade glioma), expand the pipeline into adult oncology, which included the acquisition of Mersana Therapeutics, and ultimately Day One’s acquisition by Servier. Previously, Ms. Roberson led HR at Bellicum Pharmaceuticals and at Achaogen, where she supported the companies’ expansions, pre-commercial and commercial launch preparations, as well as restructuring and workforce transitions. Earlier in her career, she spent six years at Genentech, a member of the Roche Group, as an HR Business Partner supporting commercial franchises, including the build of the Ocrevus® (MS) and Hemlibra® (hemophilia) franchises. She also held HR leadership roles of increasing responsibility at Blue Shield of California, Levi Strauss & Co. and Williams-Sonoma, Inc. Ms. Roberson holds a Bachelor of Arts from Rice University and a Master of Music in Violin Performance from the San Francisco Conservatory of Music.

The Compensation Committee of Immunic’s Board of Directors granted Ms. Roberson an initial equity option to purchase 190,000 shares of common stock of the company under the Immunic, Inc. 2026 Inducement Equity Compensation Plan (the “Options”). The Options were granted as an inducement material to Ms. Roberson’s commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). The Options will be time vested, with 25% vesting on the one-year anniversary of October 19, 2026 and the remainder vesting on a monthly basis in 36 equal installments.
 

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company’s lead development program, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials for the treatment of relapsing multiple sclerosis, with top-line data expected to be available by the end of 2026. Initiation of an additional Phase 3 clinical trial in progressive MS is expected later in 2026. Vidofludimus calcium has already shown therapeutic potential and a favorable safety and tolerability profile in Phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). The company’s development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic’s development programs and the targeted diseases; the potential for Immunic’s development programs to safely and effectively target diseases; preclinical and clinical data for Immunic’s development programs; the feasibility of advancing vidofludimus calcium to a confirmatory Phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials, anticipated clinical milestones and regulatory approvals; the nature, strategy and focus of the company and further updates with respect thereto; the development and commercial potential of any product candidates of the company; expectations regarding the capitalization, resources and ownership structure of the company; and the executive and board structure of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.
 

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
LifeSci Advisors
Joyce Allaire
immunic@lifesciadvisors.com

US Media Contact
Real Chemistry
media@imux.com

PRESS RELEASE

 

Pentixapharm Highlights Growing International Evidence Supporting Phase 3 PANDA Study in Primary Aldosteronism at EANM 2026

 

• Published research and new congress data from Europe and Asia show that Pentixafor PET can identify unilateral primary aldosteronism with high specificity, reinforcing the rationale for the Phase 3 PANDA study

• Multiple scientific contributions, mainly from independent academic groups in Europe and Asia, reflect strong interest in CXCR4, the biological target of Pentixapharm’s diagnostic and therapeutic programs

• Pentixapharm advances preparations for its pivotal U.S.-centric Phase 3 PANDA study, authorized to proceed by the FDA and designed to evaluate non-invasive subtyping to help guide the choice between surgery and medical treatment in hypertensive patients with underlying primary aldosteronism

 

Berlin, Germany, October 19, 2026 – Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), a clinical-stage biotechnology company developing radiopharmaceutical diagnostics and therapeutics, today reported that data being presented at the Annual Congress of the European Association of Nuclear Medicine (EANM 2026) in Vienna add to the growing international evidence for Pentixafor PET in primary aldosteronism, the indication of its pivotal Phase 3 PANDA study of [⁶⁸Ga]Ga-PentixaFor PET/CT. The aim is to identify, with a simple scan, the patients with one-sided disease who can benefit from surgery, and to reduce the need for adrenal vein sampling, the current standard of care and an invasive catheter procedure.

“Our pivotal Phase 3 study PANDA will answer a clear question: can we use a simple imaging procedure to identify the patients who can be helped by surgery, and spare them the invasive and burdensome catheter examination required today?” said Dr. Dirk Pleimes, Chief Executive Officer of Pentixapharm. “Data from independent groups in Europe, Asia and Australia increasingly point in this direction, and our preparations for PANDA in the U.S. are in full swing. CXCR4 also remains central to our work in hemato-oncology, where we aim to combine imaging with targeted bone marrow conditioning before stem cell transplantation.”

PANDA and the international evidence

PANDA is designed to evaluate [⁶⁸Ga]Ga-PentixaFor PET/CT for non-invasive subtyping in adults with confirmed primary aldosteronism in a registrational setting. Primary aldosteronism is a common, underdiagnosed hormonal cause of high blood pressure. Patients with one-sided disease can benefit from surgical removal of the affected adrenal gland instead of lifelong medical therapy with mineralocorticoid receptor antagonists or aldosterone synthase inhibitors, but identifying them currently requires adrenal vein sampling. The FDA confirmed in June 2026 that the study may proceed and granted Fast Track designation for this indication in July 2026. Preparations for the study in the United States are progressing.

At EANM 2026, the prospective PENTALON study from Paris (OP-048) added a French cohort to a consistent picture from independent studies on three continents. In the Monash study from Australia (Journal of Nuclear Medicine, 2026), Pentixafor PET identified one-sided disease with high specificity, was well tolerated and was preferred by almost all patients over the catheter procedure. The first stage of the CASTUS study in the Netherlands pointed in the same direction. In PENTALON, where the disease was often not visible on CT, the investigators see a clinical role for Pentixafor PET in sparing selected patients the catheter procedure and in supporting decisions on surgery. Larger datasets from China, generated independently of Pentixapharm, complete the picture. Together, these results support the approach of the Phase 3 PANDA study.

Hemato-oncology: multiple myeloma and PENTHERA

In multiple myeloma, investigators from CHU Nantes and collaborating French centers are scheduled to present an interim analysis of [⁶⁸Ga]Ga-PentixaFor PET/CT for initial staging and treatment-response assessment on October 21 (OP-875). The presentation contributes to the growing clinical evidence supporting CXCR4-targeted molecular imaging in hematological malignancies.

These findings are particularly relevant to Pentixapharm’s broader theranostic strategy, which aims to translate CXCR4-targeted imaging into precision radiopharmaceutical treatment.Pentixapharm’s planned Phase I/II PENTHERA clinical program will investigate the combined use of PentixaFor imaging to identify CXCR4-expressing disease and [⁹⁰Y]Y-PentixaTher for targeted bone marrow conditioning prior to stem cell transplantation in patients with multiple myeloma and acute myeloid leukemia.

PentixaFor and PentixaTher are investigational radiopharmaceutical candidates. Further congress information is available at https://eanm26.eanm.org/.

 

 

About Pentixapharm

Pentixapharm Holding AG (Frankfurt Prime Standard: PTP) is a clinical-stage biotechnology company headquartered in Berlin developing innovative nuclear medicine approaches to help physicians detect, characterize, and treat serious diseases with greater precision. The Company’s compounds are designed to deliver medical radioisotopes specifically to defined biological targets – either for high-resolution molecular imaging or for targeted radioligand therapy.

Pentixapharm’s pipeline is built on CXCR4 targeting, a receptor with strong scientific validation across multiple disease areas, and encompasses diagnostic and therapeutic programs in endocrine, cardiovascular, and oncological indications. The lead program, [⁶⁸Ga]Ga-PentixaFor, is being advanced into the registrational Phase 3 PANDA study for non-invasive subtyping of primary aldosteronism. The PENTHERA program advances the CXCR4-directed theranostic platform into Phase I/II in oncology. Complementing the CXCR4 platform, Pentixapharm is also developing a next-generation antibody platform targeting CD24, an emerging immune checkpoint in difficult-to-treat cancers.

Forward-looking statements

This press release contains forward-looking statements based on the current beliefs, expectations and assumptions of the management of Pentixapharm Holding AG. These statements relate to future events, prospects or financial performance and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially, positively or negatively, from those expressed or implied by such forward-looking statements. Such factors include, among others, changes in general economic and business conditions, competitive pressures, the introduction of competing products, limited market acceptance of new products, services or technologies, regulatory developments and changes in business strategy. Pentixapharm Holding AG does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements are made only as of the date of this press release. All information provided in this press release is supplied without any warranty or guarantee as to its accuracy, completeness or timeliness. To the extent permitted by law, Pentixapharm Holding AG assumes no liability in connection with this press release.

 

Pentixapharm Investor and Media Contact

Robert-Rössle-Straße 10

13125 Berlin

Germany

E-Mail: ir@pentixapharm.com

Website: www.pentixapharm.com

 

Leipzig, 16 October 2026 – FamiCord AG (ISIN: DE000A0BL849) intends to carry out a capital increase by partially utilizing the Authorized Capital 2024/1 through the issuance of new shares representing up to 20 percent of the Company’s existing share capital. The new shares shall be offered for subscription to the Company’s shareholders. The Company targets gross proceeds from the capital increase of up to EUR 9 million. These proceeds shall be used primarily to stabilize and optimize the core business of cell and tissue banking as well as CDMO activities, to streamline the Group’s structure – including related reorganization and efficiency measures – and to evaluate and selectively pursue growth opportunities in adjacent business areas. The subscription offer is intended to be launched in November 2026. Further details of the capital increase will be announced following the final resolutions of the Management Board and Supervisory Board.

Notifying Person: Jakub Baran (CEO)

DISCLAIMER
This announcement may not be distributed or published in the United States of America (including its territories and possessions), Canada, Japan or Australia or any other jurisdiction in which such distribution or publication would be unlawful. The distribution of this publication may be restricted by law in certain jurisdictions and anyone in possession of this document or information referred to herein should inform themselves about and observe any such restrictions. Failure to comply with such restrictions may constitute a violation of the capital market laws of such countries.

This announcement does not constitute an offer of, or an invitation to subscribe for or purchase, securities of FamiCord AG in the United States of America, Germany or any other jurisdiction. No public offering has been or will be made and no prospectus has been or will be published in connection with the transaction.

Neither this publication nor its contents may form the basis of an offer in any jurisdiction. The securities referred to above may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended (the “Securities Act”). The securities of FamiCord AG have not been and will not be registered under the Securities Act.

This announcement does not constitute a recommendation regarding the placement of the securities described in this announcement. Investors should consult a professional adviser as to the suitability of the offer for the person concerned.

In the United Kingdom, this publication is directed only at (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) or (ii) persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, partnerships, etc.) (all such persons together being referred to as “Relevant Persons”). This publication must not be acted on or relied on by persons other than Relevant Persons. Any investment or investment opportunity referred to in this publication is available only to Relevant Persons and will be engaged in only with Relevant Persons.

The offer referred to herein, which is being made in Member States of the European Economic Area (each a “Relevant Member State”), is directed only at “qualified investors” as defined in Article 2(e) of the Prospectus Regulation (“Qualified Investors”). For these purposes, the term “Prospectus Regulation” means Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market and repealing Directive 2003/71/EC and includes the related delegated regulations.

No action has been taken that would permit an offering of the securities, their acquisition or the distribution of this publication in countries where this is not permitted. Any person into whose possession this publication comes is required to inform themselves about and to observe any such restrictions.

OTHER
This publication constitutes neither an offer to sell nor a solicitation to buy securities. This announcement may not be distributed or published in the United States of America (including its territories and possessions), Canada, Japan or Australia or any other jurisdiction in which such publication would be unlawful. This announcement does not constitute a recommendation to buy or sell the securities described in this announcement.
 

Media Release – ad hoc announcement pursuant to Art. 53 LR

Definitive interim result of the public tender offer of Samsung Biologics Co., Ltd.

Baar, Switzerland, 16 October 2026 – Samsung Biologics Co., Ltd. (“Samsung Biologics”), through its direct subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the definitive interim result of its public tender offer (the “Offer”) for all publicly held registered shares of PolyPeptide Group AG (“PolyPeptide”) (SIX: PPGN).

The main offer period of the Offer ended on 12 October 2026, at 4:00 p.m. Swiss time. According to the definitive interim result as published by Samsung Peptide,

• the participation of Samsung Peptide and the persons acting in concert with Samsung Peptide amounts to 29,123,892 PolyPeptide shares in aggregate, corresponding to 87.92% of the issued share capital and voting rights of PolyPeptide (participation rate); and
• 29,014,418 PolyPeptide shares were tendered into the Offer until the end of the main offer period of the Offer, corresponding to 87.59% of the issued share capital and voting rights of PolyPeptide and 87.88% of all PolyPeptide shares to which the Offer relates (success rate).

The definitive interim result that has been published today by Samsung Peptide is available at https://samsungbiologics.com/offer. The provisional and the definitive end result of the Offer will be published after the end of the additional acceptance period (see below).

According to the definitive interim result as published by Samsung Peptide,

• the Offer condition pursuant to section B.7.1(a) (Minimum Acceptance Rate) of the offer prospectus of Samsung Peptide dated 31 August 2026 (the “Offer Prospectus”) has been satisfied; and
• the Offer condition pursuant to section B.7.1(d) (No Material Adverse Effect) of the Offer Prospectus has been satisfied.

In its definitive interim result, Samsung Peptide has declared the Offer successful (zustande gekommen), subject to the satisfaction of certain remaining Offer conditions, including among others the receipt of regulatory approvals in certain jurisdictions as well as the removal of the transfer restrictions and voting limitations from PolyPeptide’s articles of association and the election of the persons nominated by Samsung Biologics to the board of directors of PolyPeptide by resolution of an extraordinary general meeting of PolyPeptide. PolyPeptide has invited for an extraordinary general meeting to be held on 26 October 2026 to resolve on these matters.

According to the definitive interim result as published by Samsung Peptide, the additional acceptance period of ten (10) trading days for the subsequent acceptance of the Offer will commence on 19 October 2026 and end on 30 October 2026, 4:00 p.m. Swiss time, in accordance with section B.6 (Additional Acceptance Period) of the Offer Prospectus.

According to the definitive interim result as published by Samsung Peptide, based on the current understanding of the regulatory approval procedures in various countries as set out in the Offer Prospectus (see the Offer condition pursuant to section B.7.1(b) (Merger and FDI Clearances)), it is expected that, subject to the satisfaction of all Offer conditions, the settlement of the Offer indicated in the Offer Prospectus to take place on 13 November 2026 will be postponed in accordance with section B.7.3 of the Offer Prospectus, and that the transaction is currently expected to be completed towards the end of 2026 or in Q1 2027.

According to the definitive interim result as published by Samsung Peptide, Samsung Peptide intends to pursue a squeeze-out of any remaining public shareholders and to apply to SIX Exchange Regulation for the delisting of the PolyPeptide shares following the settlement of the Offer.

 

Contact

PolyPeptide Group AG
Strategic Marketing and Corporate Communications
Laura Rosso
mediateam@polypeptide.com
T: +41 43 502 0580

PolyPeptide Group AG
Finance / Investor Relations
Tim Brandl
investorrelations@polypeptide.com 
T: +41 43 502 0580

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com.

@PolyPeptide — follow us on LinkedIn

About Samsung Peptide and Samsung Biologics

Samsung Peptide is a direct subsidiary of Samsung Biologics. Samsung Biologics and PolyPeptide have concluded a transaction agreement on 17 July 2026 regarding the Offer. Samsung Peptide is acting as the formal offeror of the Offer. Samsung Biologics (KRX: 207940.KS) is a leading Contract Development & Manufacturing Organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, and 60,000 from the acquisition of a manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds total global manufacturing capacity of 845,000 liters. Samsung Biologics has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities. Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity. Samsung Biologics’ global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. Samsung Biologics is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health. For more information, please visit https://samsungbiologics.com. 

Legal Notice and Disclaimer

No Offer / Offer Restrictions

The information in this media release is for informational purposes only. It does not constitute, or form part of, any offer or invitation to purchase, sell, exchange or issue, or any solicitation of an offer to sell, purchase, exchange or subscribe to, any registered shares or other securities of PolyPeptide or any other person, nor shall it form the basis of, or be relied upon in connection with, any contract in relation thereto. This media release is not part of Samsung Peptide’s publication of the definitive interim result of the Offer or any other publication, communication or other documentation of Samsung Peptide or Samsung Biologics relating to the Offer, including without limitation the Offer Prospectus (the “Offer Documentation”). Terms and conditions of the Offer have been published by Samsung Peptide and Samsung Biologics in the Offer Documentation. Shareholders of PolyPeptide are urged to read the Offer Documentation, which is available at https://samsungbiologics.com/offer.

This announcement is not for publication, release or distribution in any country or jurisdiction in which it would be considered unlawful or otherwise violate any applicable laws or regulations, or which would require Samsung Peptide or Samsung Biologics to change or amend the terms or conditions of the Offer in any way, to make an additional filing with any governmental, regulatory or other authority or take additional action in relation to the Offer. Full Offer restrictions can be found in Samsung Peptide’s Offer Prospectus at https://samsungbiologics.com/offer.

Forward-looking Information and Statements

This media release has been prepared by PolyPeptide and includes forward-looking information and statements concerning the outlook for the Group’s business. These statements are based on current expectations, estimates and projections about the factors that may affect the Group’s future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as ‘expects’, ‘believes’, ‘estimates’, ‘targets’, ‘plans’, ‘projects’, ‘outlook’ or similar expressions. There are numerous risks, uncertainties and other factors, many of which are beyond PolyPeptide’s control, that could cause the group’s actual results to differ materially from the forward-looking information and statements made in this media release and that could affect the group’s ability to achieve its stated targets. Although PolyPeptide believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.

Except as otherwise required by law, PolyPeptide disclaims any intention or obligation to update any forward-looking statements as a result of developments.

 

• Marc-Alexander Mahl appointed to the Fresenius Management Board; Mahl succeeds Pierluigi Antonelli and will be responsible for the Fresenius Kabi businesses
• Fresenius CFO Sara Hennicken’s contract extended for another five years
• Sébastien Guery assumes overall responsibility for the Nutrition business at Fresenius Kabi
• Leadership team set for the next phase of #FutureFresenius

The Supervisory Board of Fresenius has unanimously appointed Dr. Marc-Alexander Mahl (58) to the Fresenius Management Board, effective November 1, 2026. He will be responsible for the Fresenius Kabi businesses. Mahl succeeds Pierluigi Antonelli, who is leaving the company for personal reasons. At the same time, the Supervisory Board has extended the contract of Chief Financial Officer (CFO) Sara Hennicken (46) for another five years. Her contract will therefore run until 2032.

“On behalf of the Supervisory Board, I would like to thank Pierluigi Antonelli for our successful collaboration built on mutual trust. Thanks to the consistent implementation of #FutureFresenius at Fresenius Kabi, all businesses are now excellently positioned in their respective growth markets and make a significant contribution to the company’s success. We wish Mr. Antonelli all the very best in his future endeavors,” said Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius. He added: “At the same time, I am delighted that in Marc-Alexander Mahl we have been able to bring an accomplished physician and experienced executive with more than 20 years of leadership experience at Fresenius to the Group Management Board. He is already responsible for two strategically important businesses, Pharma and Nutrition, and has played a key role in shaping their strategic direction as part of #FutureFresenius. The focus now is on consistently expanding the Biopharma, MedTech and Nutrition growth vectors. We very much look forward to working with him in his expanded role and are confident that he will continue the growth trajectory of all Fresenius Kabi businesses.”

Marc-Alexander Mahl will continue to lead the Pharma Business Unit. Given its growing strategic importance, the Nutrition business will in future be managed as a standalone Business Unit under the leadership of Sébastien Guery. Guery has been responsible for the Nutrition business since April 2024 and previously held several management positions at other international companies, including Sandoz, DuPont Nutrition & Biosciences and McKinsey. In his expanded role, Guery will report directly to Marc-Alexander Mahl, who is responsible for the Fresenius Kabi businesses on the Fresenius Management Board.

At the same time, the Supervisory Board has extended the contract of CFO Sara Hennicken for another five years. Her contract will now run until 2032. “Sara Hennicken has played a pivotal role in shaping the successful execution of #FutureFresenius from the very beginning. Thus, we very much look forward to continuing our successful collaboration with her,” said Kirsch.

“I would like to congratulate Sara Hennicken and Marc-Alexander Mahl and very much look forward to continuing our work together on the Management Board. On behalf of the Management Board, I would also like to thank Pierluigi Antonelli for the excellent collaboration over the past years and wish him all the very best for the future. Looking ahead, the medical nutrition business will play an even more important role for the company as a whole. I am therefore very pleased that Sébastien Guery will now assume overall responsibility for the Nutrition business,” added Michael Sen, Chief Executive Officer of Fresenius.

Leadership team set for the next phase of #FutureFresenius
With these decisions and the further strengthening of its operating businesses, Fresenius is putting its leadership team in place for the next phase of #FutureFresenius and underscoring its ambition to create sustainable value through profitable, innovation-driven growth.

Dr. Marc-Alexander Mahl has headed Fresenius’ Pharma and Nutrition businesses since May 2023. In addition, he oversees sustainability activities in these businesses. Mahl has been with Fresenius since July 2001, with a brief interruption, and has since held various management positions with regional and global responsibilities. Since 2011, he has been responsible for the global Pharma business. In parallel, Mahl served as President of Medicines for Europe and as a member of the Executive Committee of the German industry association for specialized nutrition. Mahl studied medicine, is a specialist in transfusion medicine and holds an MBA from INSEAD.

Sara Hennicken has been Chief Financial Officer of Fresenius since September 2022. In this role, she is responsible for Finance, IT and Cybersecurity. She joined the company in 2019 as Senior Vice President Global Treasury & Corporate Finance for Fresenius and Fresenius Medical Care. Prior to that, she spent 14 years in investment banking, most recently serving as Managing Director at Deutsche Bank. From 2005 to 2010, Hennicken worked at Citigroup in Frankfurt and London. She studied economics in Germany and the United States.

# # #

Fresenius (XFRA: FRE, OTC: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, medical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe’s largest private hospital operator, treating around 27 million patients annually.

With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025.

For more information, visit www.fresenius.com and follow Fresenius on LinkedIn.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Dr. Michael Moser, Dr. Christian Pawlu 
Chairman of the Supervisory Board: Wolfgang Kirsch

Press Contact:
Edith Müller-Callsen
Group Communications
Fresenius SE & Co. KGaA 
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
M +49 160 9968 4046
edith.mueller-callsen@fresenius.com

invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal

• Publication in Molecular Therapy Oncology reports Phase 1 data from 17 patients with advanced, treatment-refractory solid tumors
• Decentralized point-of-care manufacturing of APN401 was feasible across manufacturing sites
• APN401 demonstrated a favorable safety profile, with no dose-limiting toxicities or grade ≥3 treatment-related adverse events
• Disease stabilization was observed in 5 of 10 RECIST-evaluable patients

Vienna, Austria, 15 October 2026: invIOs GmbH (“invIOs”), a privately held biotechnology company developing innovative cancer immunotherapies, today announced the publication of new clinical data with its autologous PBMC (peripheral blood mononuclear cell) therapy APN401 in the peer-reviewed journal, Molecular Therapy Oncology. The publication, “Phase I Evaluation of APN401, an Autologous CBL-B–Silenced PBMC Therapy, in Advanced Solid Tumors”, reports findings from two Phase 1 studies evaluating APN401 in patients with advanced, treatment-refractory solid tumors.

A total of 17 patients received APN401 across three dose levels. The patients had advanced solid tumors and had received between two and eleven prior lines of systemic therapy. The treatment was well tolerated, with no dose-limiting toxicities, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or grade ≥3 treatment-related adverse events. The highest dose of 4.5 × 10⁷ PBMCs/kg was selected as the recommended Phase 2 dose.

Disease stabilization was observed in 5 out of 10 RECIST-evaluable patients. Exploratory immune profiling identified systemic changes following APN401 treatment, including increased levels of cytotoxic mediators and expansion of specific T-cell populations. These changes were most pronounced in patients with stable disease. This suggests that APN401 can enhance immune activity against the tumor and that this effect may be linked to clinical benefit.

APN401 is an autologous cell therapy utilizing patients’ own PBMCs in which the intracellular immune checkpoint CBL-B is transiently silenced using siRNA. CBL-B acts as a brake on the immune system: it negatively regulates antigen receptor signaling and T-cell activation. By temporarily reducing CBL-B activity in immune cells, APN401 cell therapy is engineered to overcome the immunosuppressive tumor microenvironment and attack tumor cells.

Romana Gugenberger, PhD, Managing Director of invIOs, commented: “We are thrilled to see our clinical data with APN401 published in a peer-reviewed journal. We are encouraged by the favorable safety profile, the disease stabilization observed, and the systemic immune changes following treatment. This is especially noteworthy considering that these patients had already received multiple prior lines of therapy. These results highlight the promise of CBL-B silencing as a new approach in immuno-oncology and demonstrate that our EPiC cell manufacturing platform can reliably produce cell therapies through a rapid, decentralized manufacturing process. Together, these findings support further clinical evaluation of APN401 and our EPiC platform as we work towards new treatment options for patients with difficult-to-treat solid tumors.”

APN401 is produced using invIOs’ proprietary EPiC® point-of-care platform, which allows for manufacturing of the cell therapy product with a vein-to-vein time of less than 24 hours. The study demonstrated reproducible manufacturing across sites and supported the feasibility of repeated administration.

About invIOs

invIOs is a privately held biotech company based in Vienna, Austria, focusing on the discovery and development of novel cancer therapies. The invIOs team applies its extensive knowledge of immune system activation to create personalized and targeted therapies for solid tumors. The company is progressing a pipeline of four programs that include both cell therapy and small molecule strategies. invIOs is also partnered with leading institutions and universities, including the Dana-Farber Cancer Institute, to co-develop treatments for glioblastoma. EPiC, invIOs’ proprietary cell therapy platform, allows the creation of personalized cell therapies based on localized processing of a patient’s fresh immune cells, enabling rapid treatment in an out-patient setting.

The platform’s lead asset, APN401, has successfully completed Phase 1 clinical trials in patients with various solid tumors. A second candidate, INV441, is currently being developed for glioblastoma and a first-in-human Phase 1 clinical trial is in planning. Additionally, INV451, the third EPiC-based program, represents a next-generation CAR-T cell approach targeting rare tumor types.

INV501 is a novel orally available small molecule candidate that can selectively enhance anti-tumor immune responses. It induces T-cell activation, proliferation, and tumor-specific cytotoxicity. INV501 has demonstrated favorable bioavailability and preclinical proof of concept with strong data in multiple solid tumor indications.

For further information, please visit www.invios.com and connect with us on LinkedIn.

Contacts

invIOs Romana Gugenberger, PhD Managing Director T +43 1 8656577 0 Email: investors@invios.com

MC Services AG Dr. Cora Kaiser, Dr. Regina Lutz T +49 89 210 228 0 US: Laurie Doyle T +1-339-832-0752 Email: invios@mc-services.eu

Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board

Will lead Evotec’s global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovation Brings more than 25 years of global experience in pharma, biotechnology and academia

Hamburg, Germany, October 15, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the appointment of Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board, effective November 1, 2026. Dr. Holbrook brings to Evotec more than 25 years of experience as both a scientist and R&D leader, applying novel technologies and data approaches to the challenges of drug discovery and advancing programs toward the clinic. Her experience spans multi-modal ‘omics, data science, novel therapeutic modalities and precision medicine, complemented by experience in commercializing innovative technologies, shaping drug discovery partnerships and leading therapeutic research portfolios. At Evotec, Dr. Holbrook will draw on recent scientific advances to help customers and partners discover and develop new medicines faster and with a higher probability of success.

Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:

“Joanna has a keen understanding of how data, AI and new technologies are transforming drug discovery and development today. She combines this forward-looking perspective with deep scientific expertise and a strong focus on generating robust, actionable results. I look forward to working with her as we continue to strengthen Evotec’s position as a leading partner for any organization that strives to bring new, groundbreaking medicines to market.”

Dr. Holbrook most recently served as Therapy Area Head, Cardiovascular, Renal and Hepatic Disease and Head of in vitro Discovery Platforms at Novo Nordisk. Prior to that she held positions at UK biotech companies Biomodal, where she served as Chief Scientific Officer, and BenevolentAI, where she was Vice President, Translational Medicine. She was also Professor of Bioinformatics at the University of Southampton and Senior Principal Investigator at the Singapore Institute for Clinical Sciences (A*STAR) and adjunct Professor at National University of Singapore. She started her career at GSK, where she held positions of increasing responsibility across therapy areas and bioinformatics. She holds a Ph.D. in Molecular Cell Biology from University College London and a B.Sc. in Genetics from the University of Newcastle.

Dr. Joanna Holbrook, Evotec’s incoming Chief Scientific Officer, added:

“Evotec has exceptional breadth of scientific expertise and capabilities spanning drug discovery, drug development and manufacturing. I am excited by the opportunity to work across the business to strengthen our scientific differentiation, build integrated solutions to the most important challenges in drug discovery, and develop new capabilities that are unique to Evotec.”

 

About Evotec SE

Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of around 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

 

Forward-looking statements

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

 

Investor Relations and Media Contact

Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com

 

BIOTECH SUMMIT AUSTRIA Highlights Growing Momentum
Across Austria’s Biotech Sector

Innsbruck, Austria – October 15, 2026. The fourth BIOTECH SUMMIT AUSTRIA brought together leading voices from research, industry, startups, investment and policy in Innsbruck this week. Jointly organized by BIOTECH AUSTRIA, Human.technology Styria and Standortagentur Tirol, the summit serves as a national meeting point for Austria’s biotech sector with growing international participation and this year drew more than 250 participants from 12 countries.

Held under the motto “Start up, Scale up, Step up!”, the program reflected the journey from scientific discovery and company creation through financing and organizational growth to international expansion and long-term impact. Across the two-day agenda, keynotes, panel discussions, workshops and startup pitches explored the opportunities, challenges and next steps for Austria’s biotech community as it continues to grow and connect internationally.

Peter Llewellyn-Davies, President of BIOTECH AUSTRIA, commented: “Austria has a strong scientific foundation, but one decisive question is how we translate that strength into companies that can grow and compete internationally. This year’s summit brought together researchers, entrepreneurs, investors and policymakers who all play a role in making that transition possible. The discussions demonstrated the growing ambition of the Austrian biotech sector as well as the importance of continued collaboration to unlock its full potential. My thanks go to our speakers, participants, sponsors and co-hosts for making Innsbruck such a productive meeting point for the sector.”

The keynote program featured former STADA AG CEO Claudio Albrecht, who explored how geopolitical shifts, technological innovation, changing healthcare systems and new business models could shape the pharmaceutical industry through 2035. Karl Nehammer, Vice President of the EIB and former Federal Chancellor of Austria, addressed the conditions needed for European biotech innovators to grow and compete globally. Olympic sailing champion Lukas Mähr drew on his experience to explore resilience and teamwork, while Stefan Haubner, Founding Partner at APEX Ventures, considered whether European venture capital needs a model of its own. Further sessions addressed topics such as venture financing, global IP strategy, AI in biotech investment and Austrian biotech strategy and policy. The program concluded with a fireside chat between BioNTech founder and investor Christoph Huber and Peter Llewellyn-Davies, reflecting on experiences and lessons from building successful biotech ventures.

Anton Mattle, Governor of Tyrol, commented: “Biotechnology is an important driver of innovation and future economic development. Events such as the BIOTECH SUMMIT AUSTRIA showcase Tyrol’s strengths in life sciences and create valuable connections between science, business and policy. They also contribute to strengthening Austria’s international visibility and support the exchange of ideas and partnerships that help innovative companies grow.”

Networking and partnering remained a central element of the summit. Dedicated 1:1 meetings and social events gave participants from across the biotech value chain opportunities to establish new relationships, deepen existing connections and explore future potential collaborations beyond the conference sessions.

Marcus Hofer, CEO of Standortagentur Tirol and local host of the summit, and Lejla Pock, CEO of Human.technology Styria, added: “Bringing the summit to different regions allows us to showcase their individual strengths while fostering exchange and collaboration across Austria’s biotech community and beyond. Innsbruck provided an excellent setting for discussions, new connections and future partnerships. We look forward to building on this momentum when the summit moves to Graz in 2027.”

The fourth BIOTECH SUMMIT AUSTRIA concluded with a closing reception and a handover to the next host location: The discussions in Innsbruck reflected a sector that is gaining momentum, strengthening international connections and working together to translate scientific excellence into lasting economic and societal impact. The fifth BIOTECH SUMMIT AUSTRIA will take place in Graz on 21-22 October 2027.

For further information and to revisit highlights of the fourth BIOTECH SUMMIT AUSTRIA, please visit the BIOTECH SUMMIT AUSTRIA website.

For post-event inquiries and additional information, please contact:

BIOTECH AUSTRIA
Christine Llewellyn-Davies
Head of Operations
+43 670 6030601
Email: info@biotechaustria.org

Human.technology Styria
Lejla Pock
CEO
Eva Bucht
PR & Marketing
+43 699 188 99 708
Email: office@human.technology.at

Standortagentur Tirol
Marcus Hofer
CEO Standortagentur Tirol
Albert Bloch
Communication & Press
+43 676 843 101-270
Email: albert.bloch@standort-tirol.at

Media Contact

MC Services AG
Dr. Cora Kaiser, Dr. Johanna Kobler
+49 89 210 228 0
Email: biotechaustria@mc-services.eu

About BIOTECH AUSTRIA

Since December 2020, BIOTECH AUSTRIA has been the voice of the Austrian biotech industry, enabling and connecting a non-governmental ecosystem so that businesses can start, grow and deliver world-changing innovation. Life Sciences are a key industry in Austria, and biotechnology is one of the fastest-developing sectors with high growth dynamics and international competitiveness. BIOTECH AUSTRIA is constantly expanding its network with new members and supporters in order to gather even more expertise under one roof. BIOTECH AUSTRIA represents over 100 biotech and life science companies, from start-ups to big pharma, academic institutions, research institutes, organisations and service providers to the sector. More information can be found at www.biotechaustria.org or on LinkedIn.

About Human.technology Styria

Human.technology Styria GmbH (HTS) is a cluster organization founded in 2004 with a focus on Life Sciences. It operates in three strategic priority areas: Medical Technology, Pharmaceuticals & Biotechnology, and Health & Sustainability. Additionally, HTS is actively involved in cross-cutting topics such as Start-Ups, Digitalization, and Qualification. The cluster sees itself as a bridge-builder between research, development, and industry, aiming to create synergies, enable innovations, forge new partnerships, and enhance the national and international visibility of the region. Companies within the cluster community benefit from exclusive service offerings related to Contact Management, Business Development, Internationalization, Networking, Events, Communication, and Knowledge Transfer. Within the environment of the Styrian Life Science Cluster, there are 150 companies with 40,000 employees generating a turnover of 5 billion euros. Approximately one-third of this can be attributed to the Pharma/Biotech sector. More information can be found at www.humantechnology.at.

About Standortagentur Tirol / Health Hub Tirol

Tirol is a strong life sciences location. Successful companies and outstanding universities ensure a high research output, over 11,000 jobs and an industry turnover of almost 3 billion euros per year. Almost 100 innovative companies, institutions and universities are networked in the Cluster Life Sciences Tirol, which is based at the Standortagentur Tirol. In addition, the state of Tirol invests in a location development program for life sciences via Lebensraum Tirol Holding, which is implemented by Standortagentur Tirol and its subsidiaries. This program aims to drive innovation in the fields of medical technology, digital health, pharmaceuticals and biotechnology. Tirol is to be positioned as a top European life sciences region by 2030. One pillar of the program is the Health Hub Tirol, which works closely with the Cluster Life Sciences Tirol and Startup.Tirol to provide (lab) space and a wide range of startup services. More information can be found at www.standort-tirol.at and www.healthhub.tirol.

Frauenfeld, 15 October 2026

Press release
Ad hoc announcement pursuant to Art. 53 LR

DocMorris accelerates Rx growth to 78% in Q3; EBITDA breakeven already achieved in Q3 and revenue and EBITDA forecast for 2026 raised again

• Revenue growth of 21.5% in Q3 and 15.5% in the first nine months
• Strong acceleration of Rx growth to 78.3% versus Q3 2025; plus 33.5% versus Q2 2026
• Non-Rx up 5.5% in Q3, of which Digital Services up 46.1%
• Adjusted EBITDA of CHF 0.6 million in Q3
• Revenue and adjusted EBITDA guidance for 2026 increased

CEO Walter Hess says: “Our revenue growth accelerated again in the third quarter of 2026, demonstrating that our offering is well received by patients. We will continue to consistently leverage this Rx momentum to expand our customer base and further solidify our position in the digital healthcare market.”

CFO Daniel Wüest adds: “Thanks to the strong performance of Rx and Digital Services, as well as further improvements in cost and marketing efficiency, we already achieved our targeted EBITDA breakeven in the third quarter with adjusted EBITDA of CHF 0.6 million. Against this backdrop, we are once again raising our revenue and EBITDA guidance for the full year.”

Significantly accelerated Rx growth in the third quarter

• DocMorris increased its external revenue[1] in the third quarter of 2026 significantly by 21.5 per cent[2] year-on-year to CHF 342.7 million, while revenue increased by 22.2 per cent to CHF 327.4 million.
• In the segment Germany, external revenue increased by 22.0 per cent.
• External revenue growth for prescription medicines (Rx) accelerated in the third quarter to 78.3 per cent year-on-year; Rx external revenue was 33.5 per cent higher than in the already strong second quarter of 2026 (up 17.0 per cent in Q2 compared to Q1 2026).
• Non-Rx[3] external revenue increased by 5.5 per cent.
• The OTC business grew as planned by 3.5 per cent.
• Digital Services, comprising TeleClinic, Retail Media and Marketplace, achieved revenue growth of 46.1 per cent to CHF 13.9 million, with a further increase in earnings contribution.
• In the segment Europe, revenue increased by 12.0 per cent.
• The number of active customers[4] increased year-on-year by 1.5 million to 13.1 million. Of these, 0.2 million were added in the third quarter of 2026, with the number of new Rx customers increasing at an above-average rate.
• DocMorris achieved an adjusted EBITDA of CHF 0.6 million in the third quarter, thus reaching the targeted breakeven ahead of schedule.

Continued double-digit growth in the first nine months

• External revenue increased by 15.5 per cent to CHF 970.6 million in the first nine months of 2026 year-on-year, while revenue increased by 16.4 per cent to CHF 926.6 million.
• In the segment Germany, external revenue increased by 16.0 per cent.
• Rx growth amounted to 52.6 per cent in the first nine months, with a continued positive trend in the fourth quarter.
• Non-Rx increased by 6.2 per cent, with Digital Services growing by 62.0 per cent to CHF 41.0 million.
• In the segment Europe, revenue increased by 6.3 per cent.

In September 2026, DocMorris successfully repurchased its CHF 49.6 million convertible bond maturing in 2028. The repurchase was financed by issuing a new convertible bond maturing in 2031. This move extends the company’s maturity profile while simultaneously reducing its relative financing costs.

Outlook
Due to continued positive current trading, DocMorris is raising its guidance for 2026 again as follows:

• External revenue growth: 12.5 to 15 per cent (previously: 9 to 13 per cent);
• Adjusted EBITDA: Better than minus CHF 10 million (previously: minus CHF 10 million to minus CHF 17.5 million);
• Capital expenditure remains unchanged at below CHF 30 million.

Management confirms the target of achieving free cash flow breakeven during 2027, following the achievement of the adjusted EBITDA breakeven target during 2026 in the third quarter. Medium-term targets remain unchanged.

 

Key figures, in million CHF (unaudited)	Q3 2026	Q3 2025	Change	Change in local currency
DocMorris external revenue	342.7	282.3	21.4%	21.5%
DocMorris revenue	327.4	268.1	22.1%	22.2%
Markets
Germany external revenue	326.3	267.6	21.9%	22.0%
Germany revenue	311.0	253.5	22.7%	22.8%
Germany Rx external revenue	108.1	60.9	77.6%	78.3%
Germany non-Rx external revenue	218.2	206.8	5.5%	5.5%
Europe revenue	16.4	14.6	11.9%	12.0%

 

Key figures, in million CHF (unaudited)	9M 2026	9M 2025	Change	Change in local currency
DocMorris external revenue	970.6	854.3	13.6%	15.5%
DocMorris revenue	926.6	809.4	14.5%	16.4%
Markets
Germany external revenue	920.3	806.2	14.1%	16.0%
Germany revenue	876.4	761.3	15.1%	17.0%
Germany Rx external revenue	256.0	170.5	50.1%	52.6%
Germany non-Rx external revenue	664.2	635.7	4.5%	6.2%
Europe revenue	50.3	48.1	4.6%	6.3%

 

Investors and analyst contact
Kelvin Jörn, Head of Investor Relations
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

12 November 2026	Capital Markets Day in Heerlen (NL)
19 January 2027	Revenue 2026
18 March 2027	2026 Full-year results and outlook 2027 (hybrid/Zurich, conference call/webcast)
15 April 2027	Q1/2027 Trading Update
12 May 2027	Annual General Meeting, Zurich

 

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, telemedicine and marketplace with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands. TeleClinic is Germany’s largest telemedicine platform, connecting patients with more than 6,500 doctors. DocMorris operates leading marketplaces for health and personal care products in Southern Europe. With its broad range of products and services, DocMorris is pursuing its vision of becoming the leading digital health companion for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,186 million serving over 12 million active customers in 2025. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

Disclaimer
This announcement contains certain forward-looking statements about DocMorris AG and its business, either explicitly or implicitly. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results, financial position, performance or achievements of DocMorris AG to differ materially from the future results, performance or achievements expressed or implied by such forward-looking statements. DocMorris AG is making this announcement available as of today’s date and undertakes no obligation to update the forward-looking statements contained herein as a result of new information, future events or for any other reason.

 

 

^[1] External revenue consists of the revenue of DocMorris plus online revenue of apotal, less revenue related to supplies to apotal.

^[2] All percentages are in local currency.

^[3] Consisting of OTC business and Digital Services (TeleClinic, Retail Media, Marketplace).

^[4] Customers supplied by DocMorris, either directly or through its partners.

Heidelberg Pharma Reports on the First Nine Months of Financial Year 2026

• Phase IIa trial in multiple myeloma at the recommended Phase II dose (RP2D) of 175 µg/kg proceeding as planned
• NMPA approval for clinical trial of pamlectabart tismanitin (HDP-101) combination therapy in China
• Additional collaboration agreement signed with Huadong Medicine to jointly develop new Antibody Drug Conjugates
• New preclinical and clinical data presented at scientific meetings
• Financial figures in line with planning; Sales revenue and other income increased by 79% compared to previous year and cost reduction program successfully implemented with total cost savings of roughly 30%

Ladenburg, Germany, 15 October 2026 – Heidelberg Pharma AG (FSE: HPHA) reported today on its operational progress as well as on the Group’s financial figures for the first nine months of fiscal year 2026 (1 December 2025 – 31 August 2026).

Dr. Dongzhou Jeffery Liu, Chief Executive Officer of Heidelberg Pharma AG, commented: “The first nine months of fiscal year 2026 have been a period of important progress for Heidelberg Pharma. We have advanced the clinical development of our lead project HDP-101 (pamlectabart tismanitin), strengthened our financial position and rebuilt our early ADC pipeline through our strong strategic partnership with Huadong Medicine. In our lead program pamlectabart tismanitin, we have achieved a development milestone by obtaining the recommended Phase II dose (RP2D) of 175 µg/kg and are currently focused on advancing the clinical Phase IIa study in heavily pretreated multiple myeloma patients in Europe and the United States to generate further clinical data. Patient recruitment is progressing as planned, and we are seeing increased interest from investigators following the demonstration of a favorable safety profile and initial encouraging efficacy data for our Amanitin-based ADC. We are actively seeking potential partnerships with our three lead assets (clinical or clinical-ready stage) aiming to fast develop these drug candidates and demonstrate the clinical benefits to the cancer patients who need them.

At the same time, we are very proud to have recently received approval, together with Huadong Medicine, to conduct a combination study with pamlectabart tismanitin in China, which will be carried out by our partner.”

Peter Willinger, Chief Financial Officer of Heidelberg Pharma AG, commented: “We are convinced that the new collaboration agreement with Huadong will increase our added value and contribute to the future growth of the Company. Next to that our partner programs continue to progress as planned and generated milestone payments in the first nine months. Together with the royalty financing agreement with HealthCare Royalty and Soleus Capital, this reinforces our solid financial position and supports the confirmation of our 2026 financial guidance. Furthermore, the decrease in expenses is a result of the stringent cost savings in the last months, which will remain a focus in the future.”

Key operational developments within the company and among its partners

• Pamlectabart tismanitin (HDP-101) development program: Pamlectabart tismanitin (HDP-101), an Amanitin-based antibody-drug conjugate (ADC) targeting the BCMA antigen, is being tested in a Phase I/IIa open-label, multicenter study for the treatment of relapsed or refractory multiple myeloma, a cancer of the bone marrow. The Phase I dose escalation part of the clinical study was completed in April 2026, after treating ten patient cohorts across a dose range of 20 to 218 µg/kg. Heidelberg Pharma’s Benefit and Risk Assessment team agreed with the recommendation of the study’s Safety Review Committee (SRC), which had conducted a comprehensive review of safety, tolerability and pharmacokinetic (PK) data from the ongoing trial, and selected the dose level from Cohort 9 – 175 µg/kg – as Recommended Phase 2 Dose (RP2D).
  In the Phase I part of the study, 53 patients with relapsed or refractory multiple myeloma (RRMM) were dosed and included in the data analysis. All patients were heavily pretreated with a median of five prior lines of treatment. Pamlectabart tismanitin was well-tolerated and a maximum tolerated dose was not reached. All adverse events that occurred were reversible, and no treatment related grade 5 events were observed.
  In clinical Phase 1 study, clinical responses were observed from ≥90 µg/kg, with increasing efficacy at higher doses. Across Cohorts 5 – 9 (90 -175 µg/kg), the Overall Response Rate (ORR) was 42% (13 out of 31 evaluable patients), including seven partial responses (PR), three very good partial responses (VGPR), and three stringent complete responses (sCR). In Cohort 9 (175 µg/kg), two out of five evaluable patients achieved good response: one PR and one VGPR.
• New preclinical data from the ATAC technology platform presented at the AACR 2026 Annual Meeting: Heidelberg Pharma presented promising preclinical data from its Amanitin-based ADC HDP-103 targeting metastatic castration‑resistant prostate cancer (mCRPC) at the American Association of Cancer Research (AACR) Annual Meeting 2026 in April.
  HDP-103 demonstrated target-specific binding in human tissues and robust and durable antitumor activity in patient-derived xenograft (PDX) models. The potent anti-tumor efficacy of HDP-103, combined with a favorable half-life and a manageable safety profile, led to a comfortable therapeutic index (TI) of HDP-103 that is well in the range of other ADCs that are approved or in development for solid tumor indications. Taken together, these data warrant further clinical development of HDP-103 as a novel treatment option for mCRPC.
• Milestone payment from partner Takeda received: Partner Takeda has started clinical development of its ADC candidate (TAK-188), which utilizes the Amanitin-based ADC technology licensed from Heidelberg Pharma. With the dosing of the first patient in a Phase I/II clinical trial in patients with advanced or metastatic solid tumors, an agreed-upon development milestone was reached in January, triggering a payment to Heidelberg Pharma. Financial details were not disclosed.
• Milestone payment from partner Huadong received, programs on track: Strategic partner Huadong Medicine dosed the first patient in a clinical trial with pamlectabart tismanitin in China in March, hereby achieving an agreed-upon development milestone that triggered a payment to Heidelberg Pharma.
  The Phase I clinical trial will evaluate the safety, tolerability, pharmacokinetics and efficacy of pamlectabart tismanitin in Chinese patients with plasma cell disorders, including multiple myeloma. This bridging study is conducted in addition to the existing clinical program with this ATAC to ensure comparability of safety and efficacy across different populations. Dosing has been initiated at 140 µg/kg, a dose level previously shown to be safe and well tolerated in the Caucasian ethnicity.
  Furthermore, at the end of August it was announced that the China National Medical Products Administration (NMPA) has granted Clinical Trial Approval for a Phase Ib/II clinical trial evaluating pamlectabart tismanitin in combination therapy for the treatment of patients with relapsed/refractory multiple myeloma.
  This trial will evaluate the safety, tolerability, and preliminary efficacy of pamlectabart tismanitin in combination either with pomalidomide and dexamethasone, or with daratumumab and dexamethasone, in adult patients with relapsed/refractory multiple myeloma who have received at least one prior line of therapy. The trial will be conducted by Heidelberg Pharma’s partner Huadong Medicine in China who will bear the development cost.
• Additional collaboration agreement signed with Huadong Medicine to jointly develop new Antibody Drug Conjugates: Heidelberg Pharma and Huadong Medicine have broadened their existing partnership through joint research and development of new ADCs involving up to six targets. Under the agreement, the parties will combine and leverage their complementary technologies, expertise, and resources. This includes Heidelberg Pharma’s proprietary ATAC technology platform and other novel toxin payloads, together with Huadong’s state-of-the-art R&D capabilities. The partnership aims to create synergies and drive the development of innovative next-generation ADCs, including bispecific and multispecific ADCs.
  The new ADCs may incorporate proprietary antibodies or technologies from Huadong Medicine and may carry dual payloads. This combination is designed to improve the targeting precision and safety of the drugs, while enhancing biological efficacy and clinical benefits, thereby offering potentially transformative therapeutic options for patients with relapsed/refractory diseases. The agreement foresees that ownership of the resulting development candidates will be allocated between the partners, taking into account their respective contributions.
• Amendment to license agreement with HealthCare Royalty secures USD 20 million: In early March, a further amendment to the existing license agreement with HealthCare Royalty (HCRx), with the participation of Soleus Capital Management, L.P. (Soleus Capital), was signed. The amended agreement covers the partial monetization of Heidelberg Pharma’s future royalty payments from the global sale of Telix’s diagnostic imaging agent TLX250-Px (proposed trade name: Zircaix^®). In connection with the amendment, Heidelberg Pharma received USD 20 million from Soleus Capital upfront. An additional payment of USD 25 million from Soleus Capital will be due upon FDA approval of TLX250-Px.
  As part of the current contract extension, Heidelberg Pharma has agreed to an increase in the cap on total payments as well as certain other contractual amendments. Soleus Capital’s participation has no impact on the payment from HCRx upon FDA approval.
• Change in Executive Management Board: Chief Financial Officer Walter Miller left the Company at the end of April 2026 upon expiration of his contract and at his own request. Peter Willinger succeeded him as Chief Financial Officer effective 1 May 2026.

Events after the end of the reporting period

• New clinical data on pamlectabart tismanitin (HDP-101) presented at International Myeloma Society Annual Meeting 2026: At the Annual Meeting of the International Myeloma Society (IMS) in Glasgow, United Kingdom, in mid-September, Professor Marc Raab, Head of the Heidelberg Myeloma Center at Heidelberg University Hospital, Germany, presented new clinical data from ten patient cohorts in the ongoing study evaluating pamlectabart tismanitin in multiple myeloma. In cohorts 9 and 10, pamlectabart tismanitin consistently demonstrated a very good safety and tolerability profile. In Cohort 9 (175 µg/kg), encouraging signs of clinical efficacy were seen as two out of five evaluable patients achieved good response: one PR and one VGPR.

Results of operations, financial position and net assets

The Heidelberg Pharma Group, as of the reporting date consisting of Heidelberg Pharma AG and its three subsidiaries Heidelberg Pharma Research GmbH, HDP G250 AG & Co. KG, and HDP G250 Beteiligungs GmbH, reports consolidated figures. The two latter companies are not operationally active and affiliated to the parent company like Heidelberg Pharma Research GmbH.

The reporting period referred to below relates to the period from 1 December 2025 to 31 August 2026 (9M 2026).

In the first nine months of the 2026 financial year, the Group generated sales revenues and other income totaling EUR 11.5 million (previous year: EUR 6.4 million). This represents an increase of 79.4% and is in line with the planning. The sales revenues included in this figure rose from EUR 1.4 million the previous year to EUR 9.3 million due to milestone payments from partners. Other income amounted to EUR 2.2 million and was thus significantly lower than the previous year’s level of EUR 5.0 million – a figure that was largely driven by unrealized foreign exchange rate gains (EUR 3.4 million).

Operating expenses, including depreciation, decreased by 29.4% to EUR 19.9 million in the reporting period (previous year: EUR 28.2 million), reflecting the restructuring and disciplined cost management. Operating expenses are broken down as follows: Cost of sales increased to EUR 1.7 million (previous year: EUR 0.2 million) because of material deliveries to partners and corresponds to 9% of total costs. Research and development costs of EUR 13.3 million were significantly lower compared to last year (9M 2025: EUR 21.0 million). This decrease by 36.7% reflects the Company’s focus on the leading clinical program. R&D costs continue to represent the largest cost item, accounting for 67% of operating expenses. Administrative costs, which include the costs of holding activities, the stock exchange listing and the executive management board, decreased to EUR 4.3 million compared to the same period last year (EUR 5.0 million), which is mainly due to lower personnel costs. Administrative costs account for 21% of operating expenses. Other expenses for business development, marketing and commercial market supply activities, which mainly include personnel, but also expenses for exchange rate differences, decreased by more than half compared to the previous year from EUR 2.0 million to EUR 0.7 million and represented 3% of operating expenses.

The financial result, which is mainly made up of interest income on bank balances, amounted to EUR 0.2 million (previous year: EUR 0.7 million). The decrease is attributable to a lower investment volume and lower interest rates.

The net loss for the first nine months of the financial year decreased significantly to EUR 8.7 million compared to the previous year’s figure of EUR 21.1 million. This 58.8% improvement was mainly driven by higher revenues and lower operating expenses. Earnings per share improved accordingly from EUR -0.45 in the previous year to EUR -0.19 in the reporting period.

Cash amounted to EUR 19.8 million at the end of the third quarter (30 November 2025: EUR 15.0 million; 31 August 2025: EUR 22.9 million). Excluding financing effects (essentially HCRx/ Soleus Capital), Heidelberg Pharma recorded an average cash outflow of EUR 1.3 million per month in the first nine months of the fiscal year (previous year: EUR 2.8 million outflow).

Total assets as of 31 August 2026 amounted to EUR 42.8 million and were therefore above the figure at the comparative reporting date of 30 November 2025 (EUR 38.1 million). Equity decreased to EUR -19.3 million as a result of the loss for the period compared to the end of the 2025 financial year (EUR -10.9 million).

Financial outlook for 2026

Heidelberg Pharma confirms the full-year financial guidance issued on 26 March 2026.

The Executive Management Board expects the Heidelberg Pharma Group to generate between EUR 11.0 million and EUR 15.0 million in sales revenue and other income in the 2026 fiscal year.

Operating expenses are estimated between EUR 25.0 million and EUR 29.0 million. In addition, Heidelberg Pharma assumes that over the next few years total expenses will continue to exceed income.

If income and expenses develop as anticipated, the change in cash funds in the 2026 fiscal year for Heidelberg Pharma AG’s business operations is expected to remain stable or decline slightly compared to 2025 (EUR -14.4 million). The change in cash funds could therefore be in the range of EUR 0.0 million to EUR -4.0 million. Thus, the cash balance at the end of the 2026 fiscal year should amount to between EUR 11.0 million and EUR 15.0 million (2025: EUR 15.0 million).

The Group’s financing is secured at least until mid-2027 based on current internal planning.

The complete set of figures for the interim financial statements is available at http://www.heidelberg-pharma.com/ “Press & Investors > Announcements and Reports > Financial Reports > Interim announcement of 15 October 2026”. A conference call on this interim announcement will not be offered.

Key figures for the Heidelberg Pharma Group

In EUR thsd.	9M 2026 1 EUR thsd.	9M 2025 1 EUR thsd.
Earnings
Sales revenue	9,297	1,436
Other income	2,228	4,988
Operating expenses	(19,936)	(28,179)
of which research and development costs	(13,311)	(21,042)
Operating result	(8,411)	(21,756)
Earnings before tax	(8,251)	(21,054)
Net loss for the period / Comprehensive income	(8,676)	(21,054)
Basic earnings per share in EUR	(0.19)	(0.45)
Balance sheet as of the end of the period
Total assets	42,819	54,052
Cash	19,841	22,869
Equity	(19,323)	10,530
Equity ratio2 in %	(45.1)	19.5
Cash flow statement
Cash flow from operating activities	(12,360)	(24,818)
Cash flow from investing activities	682	(179)
Cash flow from financing activities	16,645	18,428
Cash flow from other matters	(103)	15.7
Employees (number)
Employees as of the end of the period3	35	126
Full-time equivalents as of the end of the period3	33	114

 

1 The reporting period begins on 1 December and ends on 31 August.
2 Equity / total assets
3 Including members of the Executive Management Board
Rounding of exact figures may result in differences.

Contact Heidelberg Pharma AG Sylvia Wimmer Senior Director Corporate Communications Tel.: +49 6203 1009 1004 Email: investors@hdpharma.com Wallstadter Straße 59, 68526 Ladenburg

IR/PR support MC Services AG Katja Arnold (CIRO) Managing Director & Partner Tel.: +49 89 210 228 40 Email: katja.arnold@mc-services.eu

About Heidelberg Pharma

Heidelberg Pharma is the first company to develop cancer therapies using Amanitin, a compound derived from the green death cap mushroom. The biological mechanism of action of the toxin represents a new therapeutic modality and is used as a compound in the Amanitin-based ADC technology, the so-called ATAC technology.

The lead candidate HDP-101 (INN: pamlectabart tismanitin) is a BCMA ATAC in clinical development for multiple myeloma. The candidate has been granted Orphan Drug Designation and Fast Track Designation from the FDA. A second ATAC candidate, HDP-102, is in clinical development stage in Non-Hodgkin Lymphoma. HDP-103 against metastatic castration-resistant prostate cancer and HDP-104 targeting gastrointestinal tumors such as colorectal cancer have completed preclinical development. These programs are available for partnering.

The company is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com/.

ATAC^® is a registered trademark of Heidelberg Pharma Research GmbH.

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.